Results 71 to 80 of about 728 (161)

A systematic review of present and future pharmaco‐structural therapies for hypertrophic cardiomyopathy

Clinical Cardiology, Volume 47, Issue 1, January 2024.
Hypertrophic cardiomyopathy (HCM) is an increasingly recognized genetic condition that is accompanied by a heterogeneous phenotype. The presence of outflow tract obstruction carries an increased risk for the development of heart failure, arrhythmias, and sudden cardiac death.
Mariem A. Sawan, Sindhu Prabakaran, Melroy D'Souza, Omid Behbahani‐Nejad, Matthew E. Gold, Byron Robinson Williams, Ozlem Bilen   +6 more
wiley   +1 more source

From amoeboid myosin to unique targeted medicines for a genetic cardiac disease

Frontiers in Physiology
The importance of fundamental basic research in the quest for much needed clinical treatments is a story that constantly must be retold. Funding of basic science in the USA by the National Institutes of Health and other agencies is provided under the ...
James A. Spudich
doaj   +1 more source

A scoping review identified additional considerations for defining estimands in cluster randomised trials [PDF]

OBJECTIVE: An estimand is a clear description of the treatment effect a study aims to quantify. The ICH E9(R1) addendum lists five attributes that should be described when defining an estimand.
Bi, Dongquan, Copas, Andrew, Kahan, Brennan C, Li, Fan   +3 more
core  

How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions

Monaldi Archives for Chest Disease
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children ...
Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Elena Reffo, Giovanni Di Salvo   +7 more
doaj   +1 more source

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond

The Egyptian Heart Journal
Background A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic ...
Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas   +6 more
doaj   +1 more source

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy [PDF]

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable ...
Biagini, Elena, Charron, Philippe, Desai, Milind Y., Elliott, Perry, Fernandes, Fabio, Gonzalez-Lopez, Esther, Haelst, Paul L. van, Haugaa, Kristina Hermann, Kramer, Christopher M., Maurizi, Niccolo, Meder, Benjamin, Michels, Michelle, Owens, Anjali, Yuasa, Shinsuke   +13 more
core   +2 more sources

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Ahmad Masri, Iacopo Olivotto
doaj   +1 more source

Integrating pulmonary function testing with cardiopulmonary exercise testing for enhanced stratification in hypertrophic cardiomyopathy [PDF]

Background: Cardiopulmonary exercise testing (CPET) is essential for assessing patients with hypertrophic cardiomyopathy (HCM), but the role of pulmonary function testing (PFT) in refining patient stratification remains underexplored.
Agostoni, Piergiuseppe, Baracchini, Nikita, Cadeddu, Christian, Campana, Nicola, Campodonico, Jeness, Capovilla, Teresa Maria, Capra, Nicolò, Cosimo, Carriere, Galotta, Arianna, Magrì, Damiano, Mapelli, Massimo, Mattavelli, Irene, Merlo, Marco, Nava, Alessandro, Pezzuto, Beatrice, Rossi, Maddalena, Rubbo, Filippo Maria, Salvioni, Elisabetta, Sinagra, Gianfranco, Tavčar, Irena, Vignati, Carlo, Willixhofer, Robin   +21 more
core   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1893-1896, December 2025.
wiley   +1 more source

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies

The Egyptian Heart Journal
Background Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations.
Samuel Oluwadare Olalekan, Olalekan Olanrewaju Bakare, Patrick Godwin Okwute, Ifabunmi Oduyemi Osonuga, Muinat Moronke Adeyanju, Victoria Biola Edema   +5 more
doaj   +1 more source